Combination with Marquee Raine Acquisition Corp. Values Enjoy at an Approximate Enterprise Value of $1.2 Billion, Expected to Provide More Than $450 Million of Growth Capital for Enjoy to Achieve
CHICAGO (BUSINESS WIRE) Coeur Mining, Inc.’s (“Coeur” or the “Company”) (NYSE: CDE) today published its 2020 Responsibility Report, highlighting the Company’s increased focus on transparently disclosing information regarding its environmental, social and governance (“ESG”) programs and initiatives. The report demonstrates the alignment between the Company’s commitment to
Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.
LivaNova PLC: LivaNova Reports First Quarter 2021 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.
For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million, an increase of 2.1 percent on a reported basis and a decline of 0.4 percent on a constant-currency
1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), first quarter 2021 diluted loss per share from continuing operations was $0.61. First quarter 2021 adjusted diluted earnings per share from continuing operations was $0.35. Epilepsy sales growth in the quarter reflects improving market dynamics, especially in the United States. The pace of vaccination efforts, along with patients and their caregivers willingness to seek treatment, is key to the continued recovery of the Epilepsy business, said Damie
Press release content from Business Wire. The AP news staff was not involved in its creation.
Alcon Shareholders Approve All Binding Resolutions at the 2021 Annual General Meeting
April 28, 2021 GMT
GENEVA (BUSINESS WIRE) Apr 28, 2021
Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the results of its 2021 Annual General Meeting.
Given the global COVID-19 outbreak, Alcon previously directed shareholders to send their voting instructions to the independent representative, Hartmann Dreyer Attorneys-at-Law.
Shareholders showed a high level of interest and engagement in the resolutions proposed, with a total of 347,227,434 Alcon Inc. shares, corresponding to 70.87% of the shares entitled to vote, represented.